Welcome to our dedicated page for Avid Bioservices news (Ticker: CDMO), a resource for investors and traders seeking the latest updates and insights on Avid Bioservices stock.
Company Overview
Avid Bioservices (symbol: CDMO) operates as a dedicated Contract Development and Manufacturing Organization (CDMO) specializing in the production of complex biologics. With an extensive legacy in manufacturing monoclonal antibodies, recombinant proteins, and enzymes using mammalian cell culture, the company offers comprehensive, end‐to‐end solutions that cater to the intricate needs of biotechnology and pharmaceutical companies. Emphasizing cGMP manufacturing, bioprocess optimization, and rigorous regulatory compliance, Avid Bioservices has established itself as a trusted partner through decades of focused expertise in the biologics sector.
Core Capabilities and Services
The company spans the entirety of the biologics development continuum, providing customized services that address both early-stage process development and full-scale commercial manufacturing. Key areas of service include:
- Process Development: Offering cell line development, upstream and downstream process optimization, and analytical methods development to ensure robust and scalable production.
- Clinical and Commercial Manufacturing: Delivering tailored cGMP manufacturing solutions that cover drug substance production, bulk packaging, and quality control testing, thereby supporting clinical trials as well as commercial supply chains.
- Regulatory and Quality Support: Assisting clients with regulatory submission support and stability testing, ensuring that all processes meet stringent global quality benchmarks.
Technical Expertise and Industry Position
Avid Bioservices combines decades of deep technical knowledge with state‐of‐the‐art facilities, which allows the company to navigate the full lifecycle of biologic products. Its robust integration of process development and manufacturing expertise is underscored by strategic investments in technology and capacity expansion. This positions Avid as a reliable partner in an industry where quality, scalability, and regulatory adherence are of paramount importance.
Operational Excellence
The company is recognized for its methodical approach to process optimization and risk management. By aligning operational practices with the evolving needs of the biopharmaceutical landscape, Avid Bioservices ensures efficiency and consistency in the production of high-quality biologics. Their operational model is underpinned by:
- Customizable Solutions: Tailoring services to the individual requirements of each client, from investigative research to commercial launch.
- Integrated Service Offerings: Combining process development, manufacturing, and quality control under one roof to streamline production and simplify regulatory compliance.
- Global Regulatory Compliance: Adhering to comprehensive quality systems and cGMP guidelines, which demonstrates the company’s commitment to maintaining high industry standards.
Market Significance and Competitive Landscape
Operating in a rapidly evolving biopharmaceutical market, Avid Bioservices has carved out a niche by consistently delivering end-to-end solutions that meet the complex demands of early stage research and later stage commercialization. Its service model is geared towards mitigating manufacturing risks while offering scalable production capabilities. The company’s focus on technical excellence and regulatory expertise differentiates it from other players in the CDMO sector, making it a key strategic partner for both emerging biotech innovators and established pharmaceutical companies.
Why Avid Bioservices?
Clients choose Avid Bioservices for its holistic approach to biologics manufacturing coupled with a long history of operational excellence. The integration of development and commercial manufacturing streamlines the transition from concept to market, ensuring that each biologic undergoes a rigorous quality process. This blend of expertise and comprehensive service offerings underlines the company’s ability to consistently deliver on its promise of high-quality, reliable production essential for the advancement of modern therapeutics.
Areas of Expertise
To summarize, Avid Bioservices excels in:
- Biologics Process Development and Optimization
- cGMP Clinical and Commercial Manufacturing
- Comprehensive Regulatory and Quality Support
- Tailored Service Offerings for Biotech and Pharma Clients
The company’s enduring commitment to quality and operational integrity, combined with advanced technological capabilities, makes Avid Bioservices a critical component in the development and manufacturing of modern biologic therapies. Its methodical and integrated approach provides companies with efficient access to innovative treatments, underscoring its pivotal role in the biopharmaceutical supply chain.
Avid Bioservices, Inc. (NASDAQ:CDMO) announced the promotion of Michael Alston, Jr. to vice president of operations, effective September 22, 2022. Previously the director of project engineering, Alston has led all ongoing facility expansion projects, including the Myford South expansion and a new cell and gene therapy facility. He brings over 15 years of operational and capital management experience, previously holding key roles at Sterogene Bioseperations and Merck. CEO Nick Green praised Alston's exceptional leadership in overseeing complex projects.
Avid Bioservices, a biologics contract development and manufacturing organization (CDMO), will participate in the Morgan Stanley 20th Annual Global Healthcare Conference. The event is scheduled for September 12-14, 2022, in New York City. CEO Nick Green will lead a fireside chat on September 14 from 12:55 to 1:25 p.m. Eastern. The discussion will focus on the company's commitment to high-quality services in drug development and manufacturing. Interested parties can access the live webcast or the archived version via the company's investor relations website.
Avid Bioservices announced Q1 fiscal 2023 revenue of $36.7 million, a 19% rise from last year. The company secured $41 million in new business, pushing its backlog to a record $157 million, a 43% increase year-over-year. Despite strong revenue growth, gross margin fell to 25% from 37% due to increased costs related to capacity expansions. Net income decreased to $1.6 million, with diluted EPS down to $0.02. Avid expects full-year revenue to reach between $140 million and $145 million, reflecting a 17%-21% growth target.
Avid Bioservices (NASDAQ: CDMO) appointed Dr. Pramthesh Patel as vice president of process development for its mammalian cell business. With over 30 years of experience at GSK and Bristol Myers Squibb, Dr. Patel brings expertise in biopharmaceutical manufacturing processes. His role is expected to enhance Avid's capabilities, particularly in mammalian cell process development, aligning with the company's recent plans to expand its laboratories. This expansion is projected to generate an additional $20 million in annual revenue and double its current capacity by the end of Q1 2023.
Avid Bioservices (NASDAQ:CDMO) will report its Q1 fiscal 2023 financial results on September 6, 2022, after market closure. The company, specializing in biologics contract development and manufacturing, aims to enhance patient lives by offering high-quality services to biotech and pharmaceutical firms. A webcast will occur at 1:30 PM Pacific Time to discuss these results and recent corporate developments, showcasing Avid's extensive experience over 29 years in manufacturing monoclonal antibodies and recombinant proteins.
Avid Bioservices reported Q4 revenue of $31 million, up 13% year-over-year, concluding FY 2022 with $120 million in revenue, a 25% increase from FY 2021. The company achieved operational profitability for the eighth consecutive quarter and signed $155 million in new project orders, leading to a record backlog of $153 million. For FY 2023, Avid expects revenue between $140 million and $145 million, marking a growth of 17%-21%. The company is expanding its facilities, including its new cell and gene therapy suites, expected to come online in mid-2023.
Avid Bioservices (NASDAQ:CDMO) will announce its financial results for the quarter and fiscal year ending April 30, 2022, on June 29, 2022, after market close. A conference call will follow at 1:30 PM PT (4:30 PM ET) where senior management will discuss the results and recent corporate developments. As a dedicated CDMO, Avid focuses on providing high-quality services in biologics, including CGMP manufacturing and process development for biotechnology and pharmaceutical sectors, leveraging 29 years of experience in the industry.
Avid Bioservices (NASDAQ:CDMO) has opened a new 53,000-square-foot viral vector and CGMP manufacturing facility in Costa Mesa, California, in just eight months. This facility, built in collaboration with CRB, addresses a critical market gap in oncology and rare disease treatments. The project utilized the ONEsolution™ approach, ensuring alignment on cost and schedule. The full facility will support both adherent and suspension cultures, with the second operational phase expected by mid-2023. Avid aims to enhance its capabilities in cell and gene therapy, meeting growing industry demands.
Avid Bioservices (NASDAQ: CDMO) announces the opening of its analytical and process development (AD/PD) suites in a new viral vector facility, marking eight months since its plans were revealed. This facility aims to enhance capabilities in the cell and gene therapy market, with CGMP manufacturing suites expected to be operational by mid-2023. The AD/PD labs are equipped for advanced viral vector production, focusing on AAVs and lentiviruses. This expansion is part of Avid's growth strategy, showcasing its commitment to sustainable revenue growth.
Avid Bioservices announces a significant expansion of its process development capacity for mammalian cell operations, which could enhance annual revenue by $20 million, effectively doubling current capabilities. The expansion, costing approximately $6 million, is set for completion by the end of 2022. This growth reflects Avid's commitment to meet the increasing demand for high-quality contract development and manufacturing organization (CDMO) services, enhancing its competitive edge in biotechnology and pharmaceutical sectors.
FAQ
What is the current stock price of Avid Bioservices (CDMO)?
What is the market cap of Avid Bioservices (CDMO)?
What are the primary services offered by Avid Bioservices?
How does Avid Bioservices ensure quality in its manufacturing processes?
What sets Avid Bioservices apart from other CDMOs?
What types of biologic products does Avid Bioservices manufacture?
How does Avid Bioservices support early-stage development programs?
How does Avid Bioservices maintain regulatory compliance?
